Pacific Biosciences Of California (PACB) Cash from Investing Activities (2010 - 2026)

Pacific Biosciences Of California's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $35.9 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 20.73% year-over-year to $35.9 million; the TTM figure through Mar 2026 stood at $106.1 million (down 47.84% YoY), while the FY2025 annual figure was $115.4 million, down 6.9% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $35.9 million, up from $26.0 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $242.3 million in Q3 2023, with the low at -$98.6 million in Q2 2023.
• The 5-year median for Cash from Investing Activities is $26.0 million (2025), against an average of $23.3 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities surged 414.72% in 2022, then sank 272.53% in 2023.
• Pacific Biosciences Of California's Cash from Investing Activities stood at $80.4 million in 2022, then tumbled by 182.8% to -$66.6 million in 2023, then surged by 187.48% to $58.2 million in 2024, then tumbled by 55.31% to $26.0 million in 2025, then jumped by 37.77% to $35.9 million in 2026.
• Business Quant data shows PACB's Cash from Investing Activities at $35.9 million in Q1 2026, $26.0 million in Q4 2025, and $18.9 million in Q3 2025.